Drug Trial Radar · NCT02741791
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
312
Actual
Start
Mar 2016
Primary completion
Mar 20, 2020
Study completion Mar 20, 2020
Sponsor
- Lead sponsor
- Axsome Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD). This is a randomized, double-blind, active-controlled, 12-week, two-period study consisting of an open-label, bupropion lead-in period, and a double-blind treatment period. The trial is being conducted in subjects with treatment resistant MDD. Subjects will be considered to have treatment resistant MDD if they have had a historical inadequate response to 1 or 2 antidepressant treatments and a prospective inadequate response to treatment with bupropion during the open-label, lead-in period.
Conditions
- Treatment Resistant Major Depressive Disorder
Interventions
AXS-05Drug
AXS-05 taken daily for 6 weeks.
BupropionDrug
Buproprion taken daily for 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery-Åsberg Depression Rating Scale (MADRS) total scoreTime frame: MADRS change from Baseline to End of Study (6 weeks)
Locations
74 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Beverly Hills, California
Site not named
Garden Grove, California
Site not named
Oakland, California
Site not named
Oceanside, California
Site not named
Panorama City, California
Site not named
Redlands, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Sherman Oaks, California
Site not named
Temecula, California
Site not named
Upland, California
Site not named
Colorado Springs, Colorado
Site not named
Cromwell, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Coral Springs, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Fort Myers, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Lakeland, Florida
Site not named
North Miami, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
St. Petersburg, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Skokie, Illinois
Site not named
Shreveport, Louisiana
Site not named
Baltimore, Maryland
Site not named
Saint Charles, Missouri
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Nashua, New Hampshire
Site not named
Berlin, New Jersey
Site not named
Cherry Hill, New Jersey
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.